Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)Vivian Salama, Marina Konopleva, Lisa Kays et al.|Cancer Research|2020Cited by 8